| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
This compound does not have a biological target; it is a chemical linker (PEG-based spacer) used in the synthesis of PROTACs (proteolysis-targeting chimeras) and conjugates. In PROTACs, the linker connects a ligand for an E3 ubiquitin ligase to a ligand for a target protein of interest (POI), enabling targeted protein degradation. This compound also serves as a conjugation reagent for ADCs and bioconjugates. It is a synthetic intermediate with no direct receptor or enzyme inhibition activity.
|
|---|---|
| ln Vitro |
As a linker, this compound does not possess intrinsic in vitro biological activity. Its value is in enabling the synthesis of biologically active conjugates. No direct pharmacological effects (e.g., cytotoxicity, enzyme inhibition, receptor modulation) have been reported. The PEG2 spacer reduces aggregation and improves the solubility of conjugated molecules, which is beneficial in cell-based assays. For PROTACs incorporating this linker, degradation of target proteins (e.g., BRD4, AR, ER) can be measured by Western blot in cell lines (e.g., HEK293T, HeLa).
|
| ln Vivo |
No direct in vivo activity is reported, as the compound is a synthetic linker. When incorporated into PROTACs or ADCs, the conjugates may exhibit in vivo efficacy in animal models (e.g., tumor xenograft models). For example, a PROTAC containing this linker could induce target protein degradation and tumor growth inhibition. The linker itself has no intrinsic pharmacological activity. An appropriate linker is essential for the success of in vivo studies.
|
| Enzyme Assay |
As a synthetic intermediate, this compound is not used in cell-free biological assays. However, for evaluating linker stability, plasma stability assays: the compound is incubated in human or mouse plasma (1-100 uM) at 37degC for 0-24 hours. Aliquots are taken at various time points (0, 1, 2, 4, 8, 24 hours). The reaction is quenched with acetonitrile. The remaining intact compound is quantified by LC-MS/MS. Cleavage of the chloroalkyl group (C-Cl bond) indicates chemical instability. No enzyme or receptor binding assays are applicable.
|
| Cell Assay |
Not applicable (no biological activity). For testing the stability and cell permeability of PROTACs containing this linker, cell-based assays: cells are treated with the PROTAC (0.001-10 uM) for 4-24 hours. The cells are lysed, and target protein degradation is measured by Western blot (e.g., using anti-BRD4, anti-AR, or anti-ER antibodies). The concentration required for 50% degradation (DC50) and maximum degradation (Dmax) are determined. The linker influences cellular permeability and degradation efficiency. No direct assays with the linker alone.
|
| Animal Protocol |
No direct in vivo activity. For PROTACs containing this linker, a standard in vivo xenograft protocol: female athymic nude mice are implanted subcutaneously with cancer cells (e.g., 5×10⁶ cells in Matrigel). When tumors reach ~150-200 mm3, mice are randomized. The PROTAC is administered intraperitoneally or orally daily at 10-100 mg/kg (vehicle: 5% DMSO, 30% PEG300, 5% Tween 80, 60% saline). Tumor volume is measured every 2-3 days. At the end of the study, tumors are excised for target protein analysis by Western blot and immunohistochemistry. The linker itself is not used in animal studies.
|
| ADME/Pharmacokinetics |
As a small PEG-based linker, this compound is expected to have high water solubility and moderate plasma stability. The chloroalkyl group may be susceptible to nucleophilic substitution in vivo. The PEG2 spacer reduces protein binding and enhances clearance. Pharmacokinetic parameters are not available. Powder stored at -20degC for 3 years and in solvent at -80degC for 1 year. For formulation: soluble in DMSO and water. Typically used as an intermediate, not for direct in vivo administration.
|
| Toxicity/Toxicokinetics |
Limited toxicology data are available. As a chloroalkane-containing compound, it may act as an alkylating agent and should be handled as a potential mutagen. Chloroalkyl compounds can react with nucleophilic sites in DNA and proteins, potentially causing genotoxicity. Standard safety precautions: wear gloves, lab coat, goggles; work in a fume hood; avoid inhalation and skin contact. No acute or chronic toxicity studies are available.
|
| References | |
| Additional Infomation |
2-(2-((6-Chlorohexyl)oxy)ethoxy)acetic acid is a PEG-based PROTAC linker used in targeted protein degradation research (PROTACs). It contains a terminal carboxylic acid for amide coupling to an E3 ligase ligand and a chloroalkyl group for nucleophilic substitution. The PEG2 spacer increases solubility and reduces aggregation of synthesized conjugates. It is a synthetic building block for bioconjugation and drug delivery. No clinical trials or regulatory approvals exist.
|
| Molecular Formula |
C10H19CLO4
|
|---|---|
| Molecular Weight |
238.71
|
| Exact Mass |
238.097
|
| CAS # |
2231744-57-1
|
| PubChem CID |
134695395
|
| Appearance |
Colorless to light yellow liquid
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
15
|
| Complexity |
152
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClCCCCCCOCCOCC(=O)O
|
| InChi Key |
NFVRQBNHQOLQED-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H19ClO4/c11-5-3-1-2-4-6-14-7-8-15-9-10(12)13/h1-9H2,(H,12,13)
|
| Chemical Name |
2-[2-(6-chlorohexoxy)ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1892 mL | 20.9459 mL | 41.8918 mL | |
| 5 mM | 0.8378 mL | 4.1892 mL | 8.3784 mL | |
| 10 mM | 0.4189 mL | 2.0946 mL | 4.1892 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
